CSF1R and pancreatic ductal adenocarcinoma: Moreover, blockade of CSF1/CSF1R signaling by GW2850 and PLX3397 CSF1R inhibitors or by anti-CSF-1 not only blocked TAM and M-MDSC recruitment, but also killed CD206high TAMs and reprogrammed the remaining TAMs to support anti-tumor immune activities in murine ductal pancreatic adenocarcinoma [126].